Impact of a Naturalistic Psychedelic Experience on Smoking: A Retrospective Survey

References

• Anthenelli, R. M., N. L. Benowitz, R. West, L. St Aubin, T. McRae, D. Lawrence, J. Ascher, C. Russ, A. Krishen, and A. E. Evins. 2016. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): A double-blind, randomised, placebo-controlled clinical trial. Lancet London English 387 (10037):2507–20. doi:10.1016/S0140-6736(16)30272-0.
   PubMed Web of Science ®Google Scholar
• Barrett, F. S., M. W. Johnson, and R. R. Griffiths. 2015. Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. Journal Psychopharmacol (Oxford) 29 (11):1182–90. doi:10.1177/0269881115609019.
   PubMed Web of Science ®Google Scholar
• Berkovitch, L., B. Romeo, L. Karila, R. Gaillard, and A. Benyamina. 2021. Efficacité des psychédéliques en psychiatrie, une revue systématique. L’Encéphale 47:376–87. doi:10.1016/j.encep.2020.12.002.
   PubMedGoogle Scholar
• Bogenschutz, M. P., A. A. Forcehimes, J. A. Pommy, C. E. Wilcox, P. C. R. Barbosa, and R. J. Strassman. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal Psychopharmacol Oxford English 29 (3):289–99. doi:10.1177/0269881114565144.
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P., S. Ross, S. Bhatt, T. Baron, A. A. Forcehimes, E. Laska, S. E. Mennenga, K. O’Donnell, L. T. Owens, S. Podrebarac, et al. 2022. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry 79 (10):953. doi:10.1001/jamapsychiatry.2022.2096.
   PubMed Web of Science ®Google Scholar
• Bond, F. W., S. C. Hayes, R. A. Baer, K. M. Carpenter, N. Guenole, H. K. Orcutt, T. Waltz, and R. D. Zettle. 2011. Preliminary psychometric properties of the acceptance and action questionnaire–II: A revised measure of psychological inflexibility and experiential avoidance. Behavior Therapy 42 (4):676–88. doi:10.1016/j.beth.2011.03.007.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., M. Bolstridge, J. Rucker, C. M. Day, D. Erritzoe, M. Kaelen, M. Bloomfield, J. A. Rickard, B. Forbes, and A. Feilding. 2016. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry 3 (7):619–27. doi:10.1016/S2215-0366(16)30065-7.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R., B. Giribaldi, R. Watts, M. Baker-Jones, A. Murphy-Beiner, R. Murphy, J. Martell, A. Blemings, D. Erritzoe, and D. J. Nutt. 2021. Trial of psilocybin versus escitalopram for depression. The New England Journal of Medicine 384 (15):1402–11. doi:10.1056/NEJMoa2032994.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., and D. J. Nutt. 2017. Serotonin and brain function: A tale of two receptors. Journal Psychopharmacol (Oxford) 31 (9):1091–120. doi:10.1177/0269881117725915.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., L. Roseman, E. Haijen, D. Erritzoe, R. Watts, I. Branchi, and M. Kaelen. 2018. Psychedelics and the essential importance of context. Journal of Psychopharmacology 32 (7):725–31. doi:10.1177/0269881118754710.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., F. S. Barrett, and R. R. Griffiths. 2020. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal Contextual Behavioral Science 15:39–45. doi:10.1016/j.jcbs.2019.11.004.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., Y. Xin, N. D. Sepeda, A. Garcia-Romeu, and M. T. Williams. 2021. Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chronic Stress 5:247054702110356. doi:10.1177/24705470211035607.
   Google Scholar
• Doll, R., R. Peto, J. Boreham, and I. Sutherland. 2004. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 328:1519. doi:10.1136/bmj.38142.554479.AE.
   PubMed Web of Science ®Google Scholar
• Fagerström, K., C. Russ, C.-R. Yu, C. Yunis, and J. Foulds. 2012. The fagerström test for nicotine dependence as a predictor of smoking abstinence: A pooled analysis of varenicline clinical trial data. Nicotine & Tobacco Research 14 (12):1467–73. doi:10.1093/ntr/nts018.
   PubMed Web of Science ®Google Scholar
• Fauvel, B., S. Kangaslampi, L. Strika-Bruneau, B. Romeo, and P. Piolino. 2022. Validation of a french version of the mystical experience questionnaire with retrospective reports of the most significant psychedelic experience among french users. Journal of Psychoactive Drugs 55 (2):170–79. doi:10.1080/02791072.2022.2059796.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu, A., A. K. Davis, F. Erowid, E. Erowid, R. R. Griffiths, and M. W. Johnson. 2019. Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology 33 (9):1088–101. doi:https://doi.org/10.1177/0269881119845793.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu, A., R. R. Griffiths, and M. W. Johnson. 2014. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews 7 (3):157–64. doi:10.2174/1874473708666150107121331.
   PubMedGoogle Scholar
• Haijen, E. C. H. M., M. Kaelen, L. Roseman, C. Timmermann, H. Kettner, S. Russ, D. Nutt, R. E. Daws, A. D. G. Hampshire, R. Lorenz, et al. 2018. Predicting responses to psychedelics: A prospective study. Frontiers in Pharmacology 9:897. doi:10.3389/fphar.2018.00897.
   PubMed Web of Science ®Google Scholar
• Halberstadt, A. L. 2015. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research 277:99–120. doi:10.1016/j.bbr.2014.07.016.
   PubMed Web of Science ®Google Scholar
• Hartogsohn, I. 2016. Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology 30 (12):1259–67. doi:https://doi.org/10.1177/0269881116677852.
   PubMed Web of Science ®Google Scholar
• Hartogsohn, I. 2017. Constructing drug effects: A history of set and setting. Drug Science, Policy and Law 3:2050324516683325. doi:10.1177/2050324516683325.
   Google Scholar
• Heatherton, T. F., L. T. Kozlowski, R. C. Frecker, and K. O. Fagerström. 1991. The fagerström test for nicotine dependence: A revision of the fagerström tolerance questionnaire. British Journal of Addiction 86 (9):1119–27. doi:10.1111/j.1360-0443.1991.tb01879.x.
   PubMedGoogle Scholar
• Johnson, M. W., A. Garcia-Romeu, M. P. Cosimano, and R. R. Griffiths. 2014. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology 28 (11):983–92. doi:https://doi.org/10.1177/0269881114548296.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, and R. R. Griffiths. 2017. Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse 43 (1):55–60. doi:10.3109/00952990.2016.1170135.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, P. S. Johnson, and R. R. Griffiths. 2017. An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology 31 (7):841–50. doi:https://doi.org/10.1177/0269881116684335.
   PubMed Web of Science ®Google Scholar
• Kangaslampi, S., A. Hausen, and T. Rauteenmaa. 2020. Mystical experiences in retrospective reports of first times using a psychedelic in Finland. Journal of Psychoactive Drugs 52 (4):309–18. doi:10.1080/02791072.2020.1767321.
   PubMed Web of Science ®Google Scholar
• Krebs, T. S., and P.-O. Johansen. 2012. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. Journal of Psychopharmacology 26 (7):994–1002. doi:10.1177/0269881112439253.
   PubMed Web of Science ®Google Scholar
• Leary, T., G. H. Litwin, and R. Metzner. 1963. Reactions to psilocybin administered in a supportive environment. Journal of Nervous & Mental Disease 137 (6):561–73. doi:10.1097/00005053-196312000-00007.
   PubMed Web of Science ®Google Scholar
• Madsen, M. K., P. M. Fisher, D. Burmester, A. Dyssegaard, D. S. Stenbæk, S. Kristiansen, S. S. Johansen, S. Lehel, K. Linnet, C. Svarer, et al. 2019. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacol 44 (7):1328–34. doi:10.1038/s41386-019-0324-9.
   PubMed Web of Science ®Google Scholar
• Miller, W. R. 2004. The phenomenon of quantum change. Journal of Clinical Psychology 60 (5):453–60. doi:10.1002/jclp.20000.
   PubMed Web of Science ®Google Scholar
• Monestès, J. L., M. Villatte, H. Mouras, G. Loas, and F. W. Bond. 2009. Traduction et validation française du questionnaire d’acceptation et d’action (AAQ-II). European Review of Applied Psychology 59 (4):301–08. doi:10.1016/j.erap.2009.09.001.
   Web of Science ®Google Scholar
• National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. 2014. The health consequences of smoking—50 years of progress: a report of the surgeon general, reports of the surgeon general. In Centers for disease control and prevention (US), Atlanta (GA), Georgia, United state.
   Google Scholar
• Palhano-Fontes, F., D. Barreto, H. Onias, K. C. Andrade, M. M. Novaes, J. A. Pessoa, S. A. Mota-Rolim, F. L. Osório, R. Sanches, and R. G. dos Santos. 2019. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine 49 (4):655–63. doi:10.1017/S0033291718001356.
   PubMed Web of Science ®Google Scholar
• Pasquereau, A., R. Andler, P. Arwidson, R. Guignard, and V. Nguyen-Thanh. 2020. Tobacco use among adults: Five-year review of the national tobacco control programme, 2014-2019. Bull Epidémiol Hebd 14:273–81.
   Google Scholar
• R Core Team. 2018. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. https://www.R-project.org/
   Google Scholar
• Rigotti, N. A., G. R. Kruse, J. Livingstone-Banks, and J. Hartmann-Boyce. 2022. Treatment of Tobacco Smoking: A Review. JAMA 327 (6):566. doi:10.1001/jama.2022.0395.
   PubMed Web of Science ®Google Scholar
• Romeo, B., M. Hermand, A. Pétillion, L. Karila, and A. Benyamina. 2021. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. Journal of Psychiatric Research 137:273–82. doi:10.1016/j.jpsychires.2021.03.002.
   PubMed Web of Science ®Google Scholar
• Sessa, B. 2012. The psychedelic renaissance: Reassessing the role of psychedelic drugs in 21st century psychiatry and society. London, United Kingdom: Muswell Hill Press.
   Google Scholar
• Simonsson, O., W. Osika, R. Carhart-Harris, and P. S. Hendricks. 2021. Associations between lifetime classic psychedelic use and cardiometabolic diseases. Scientific Reports 11 (1):14427. doi:10.1038/s41598-021-93787-4.
   PubMed Web of Science ®Google Scholar
• Simonsson, O., J. D. Sexton, and P. S. Hendricks. 2021. Associations between lifetime classic psychedelic use and markers of physical health. Journal of Psychopharmacology 35 (4):447–52. doi:https://doi.org/10.1177/0269881121996863.
   PubMed Web of Science ®Google Scholar
• Teixeira, P. J., M. W. Johnson, C. Timmermann, R. Watts, D. Erritzoe, H. Douglass, H. Kettner, and R. L. Carhart-Harris. 2022. Psychedelics and health behaviour change. Journal of Psychopharmacology 36 (1):12–19. doi:https://doi.org/10.1177/02698811211008554.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2022. https://www.who.int/news-room/fact-sheets/detail/tobacco
   Google Scholar